23andMe and its user data will soon belong to a pharmaceutical giant
23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech company Regeneron Pharmaceuticals announced an agreement on Monday to purchase the 23andMe startup for $256 million, alongside its Total Health and Research Services business and biobank of customer data and genetic samples…
23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech company Regeneron Pharmaceuticals announced an agreement on Monday to purchase the 23andMe startup for $256 million, alongside its Total Health and Research Services business and biobank of customer data and genetic samples…
Read More
About Author
